Related Experiment Videos
Preliminary results with an oral application of killed Purtussis bacteria in newborn infants
Developments in Biological Standardization
|January 1, 1976
Insights
Oral vaccination of newborn infants using a Bordetella pertussis vaccine demonstrated promising antibody responses. This study explored the efficacy of an oral pertussis vaccine in a small cohort of newborns.
Area of Science:
- Immunology
- Pediatrics
- Microbiology
Background:
- Pertussis (whooping cough) remains a significant global health concern, particularly for infants too young to be fully vaccinated.
- Current pertussis vaccines are administered intramuscularly, posing challenges for neonatal administration and potentially impacting early immune development.
Purpose of the Study:
- To evaluate the immunogenicity of an orally administered vaccine containing killed Bordetella pertussis in newborn infants.
- To determine the feasibility and safety of oral pertussis vaccination in the neonatal period.
Main Methods:
- Newborn infants received an oral vaccine containing 10(11) killed Bordetella pertussis.
- Vaccination was administered daily for five consecutive days.
- Antibody titres were measured in the subjects post-vaccination.
Main Results:
- Eight out of twelve infants developed detectable antibody titres against Bordetella pertussis.
- Antibody titres ranged from 1:20 to 1:80, indicating a measurable immune response.
- The oral vaccination route was utilized for all participating infants.
Conclusions:
- Oral administration of a killed Bordetella pertussis vaccine in newborns can elicit detectable antibody responses.
- Further research is warranted to optimize dosage, vaccination schedules, and assess the long-term efficacy and safety of oral pertussis vaccines.
Abstract:
Newborn babies have been vaccinated orally on five consecutive days, with 5 droplets of a vaccine containing 10(11) killed Bordetella pertussis. Eight out of twelve subjects showed antibody titres varying between 1:20 and 1:80.